EU Approves Enhertu-Pertuzumab in First-Line HER2-Positive Breast Cancer

Companies: AstraZeneca / Daiichi Sankyo · Drugs: Enhertu (Trastuzumab Deruxtecan) + Pertuzumab · Trial: DESTINY-Breast09 (Phase III) · Indication: First-Line HER2-Positive Metastatic Breast Cancer · Date: September 1, 2026 Summary The European Commission approved trastuzumab deruxtecan plus pertuzumab for first-line treatment of adults with unresectable…